The microbiota-gut-brain axis

JF Cryan, KJ O'Riordan, CSM Cowan… - Physiological …, 2019 - journals.physiology.org
I. INTRODUCTION 1877 II. STUDYING THE... 1881 III. MICROBIOTA-GUT-BRAIN AXIS...
1907 IV. PATHWAYS OF COMMUNICATION 1911 V. MICROBIOTA AND SYNAPTIC... 1929 …

[HTML][HTML] Microbiota-gut-brain axis: modulator of host metabolism and appetite

M Van de Wouw, H Schellekens, TG Dinan… - The Journal of nutrition, 2017 - Elsevier
The gut harbors an enormous diversity of microbes that are essential for the maintenance of
homeostasis in health and disease. A growing body of evidence supports the role of this …

Increased mortality in schizophrenia due to cardiovascular disease–a non-systematic review of epidemiology, possible causes, and interventions

PA Ringen, JA Engh, AB Birkenaes, I Dieset… - Frontiers in …, 2014 - frontiersin.org
Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …

[BOK][B] The Maudsley prescribing guidelines

D Taylor, C Paton - 2009 - taylorfrancis.com
One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters

KJ Davey, SM O'Mahony, H Schellekens… - …, 2012 - Springer
Abstract Rationale Atypical antipsychotic drugs (AAPDs) such as olanzapine have a serious
side effect profile including weight gain and metabolic dysfunction, and a number of studies …

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

SM Stahl, L Mignon, JM Meyer - Acta Psychiatrica Scandinavica, 2009 - Wiley Online Library
Objective: To provide an overview for practicing clinicians on the pharmacological basis of
cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness …

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

R Coccurello, A Moles - Pharmacology & therapeutics, 2010 - Elsevier
Beside the therapeutic improvement over first-generation antipsychotics, the fact that
prescription of atypical agents is also associated to the emergence of severe metabolic …

Metabolic syndrome associated with schizophrenia and atypical antipsychotics

M Hasnain, SK Fredrickson, WVR Vieweg… - Current diabetes …, 2010 - Springer
Patients with schizophrenia are at increased risk for develo** the metabolic syndrome or
its individual components due to their lifestyle, suspected genetic predisposition, and …

Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia

D Vancampfort, J Knapen, M Probst, R van Winkel… - Psychiatry …, 2010 - Elsevier
This article reviews evidence that researchers and mental health service providers need to
take into account four modifiable factors that affect the prevalence of the metabolic syndrome …

Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians

M Hasnain, WVR Vieweg, B Hollett - Postgraduate medicine, 2012 - Taylor & Francis
Second–generation antipsychotics (SGAPs) and second–generation antidepressants
(SGADs) have multiple US Food and Drug Administration–approved indications and are …